<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005823</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067831</org_study_id>
    <secondary_id>LRF-AML14</secondary_id>
    <secondary_id>EU-20016</secondary_id>
    <secondary_id>ISRCTN62207270</secondary_id>
    <nct_id>NCT00005823</nct_id>
  </id_info>
  <brief_title>Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome</brief_title>
  <official_title>A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leukemia Research Fund</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. It is not yet known if stronger doses of chemotherapy given over&#xD;
      a longer period of time are as well tolerated or as effective as less intensive chemotherapy.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying intensive regimens of chemotherapy to&#xD;
      see how well they work compared to nonintensive regimens of chemotherapy in treating older&#xD;
      patients with acute myeloid leukemia or myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the response rate, survival, quality of life, and supportive care requirements&#xD;
           with intensive versus nonintensive chemotherapy in older patients with acute myeloid&#xD;
           leukemia or high risk myelodysplastic syndrome.&#xD;
&#xD;
        -  Compare response achievement, response duration, survival, toxicity and supportive care&#xD;
           requirements with differing doses of daunorubicin and cytarabine in these patients&#xD;
           receiving intensive chemotherapy.&#xD;
&#xD;
        -  Determine the efficacy of PSC 833 in enhancing the effects of daunorubicin in these&#xD;
           patients receiving intensive chemotherapy.&#xD;
&#xD;
        -  Compare relapse rate, deaths in complete remission, disease free survival, and survival&#xD;
           with short versus long intensive chemotherapy in these patients.&#xD;
&#xD;
        -  Compare response achievement, response duration, survival, toxicity, quality of life,&#xD;
           and resource use with hydroxyurea versus cytarabine in these patients receiving low dose&#xD;
           chemotherapy.&#xD;
&#xD;
        -  Determine response achievement, response duration, survival, toxicity, quality of life,&#xD;
           and supportive care requirements with the addition of tretinoin to the nonintensive&#xD;
           chemotherapy in these patients.&#xD;
&#xD;
        -  Assess the correlation between P-gp and BCL-2 in family members and treatment outcomes&#xD;
           and other prognostic factors in these patients with these treatment regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized or electively&#xD;
      assigned to either intensive or nonintensive chemotherapy*.&#xD;
&#xD;
      Intensive chemotherapy&#xD;
&#xD;
        -  Induction therapy: Patients are randomized to 1 of 6 treatment arms. Patients receive 2&#xD;
           courses of chemotherapy comprising 1 of 2 daunorubicin doses, 1 of 2 cytarabine doses,&#xD;
           thioguanine, and with or without PSC 833.&#xD;
&#xD;
      Patients receive daunorubicin IV once daily on days 1-3 with cytarabine IV twice daily and&#xD;
      oral thioguanine once daily on days 1-10 during course 1. Treatment repeats in approximately&#xD;
      31 days as in course 1 except cytarabine and thioguanine are given only on days 1-8.&#xD;
&#xD;
        -  Arm I: Patients receive higher dose of daunorubicin, lower dose of cytarabine, and&#xD;
           thioguanine.&#xD;
&#xD;
        -  Arm II: Patients receive higher dose of daunorubicin, higher dose of cytarabine, and&#xD;
           thioguanine.&#xD;
&#xD;
        -  Arm III: Patients receive lower dose of daunorubicin, lower dose of cytarabine, and&#xD;
           thioguanine.&#xD;
&#xD;
        -  Arm IV: Patients receive lower dose of daunorubicin, higher dose of cytarabine, and&#xD;
           thioguanine.&#xD;
&#xD;
        -  Arm V: Patients receive treatment as in arm III in combination with continuous infusion&#xD;
           of PSC 833 beginning day 1.&#xD;
&#xD;
        -  Arm VI: Patients receive treatment as in arm IV in combination with continuous infusion&#xD;
           of PSC 833 beginning on day 1.&#xD;
&#xD;
      Patients with refractory disease after the first course of induction chemotherapy may&#xD;
      continue with the intensive protocol arm or enter the nonintensive arm*. Patients who do not&#xD;
      achieve complete remission after completion of induction chemotherapy are removed from study.&#xD;
      Patients in complete remission after induction therapy receive consolidation therapy.&#xD;
&#xD;
        -  Consolidation therapy: Patients in complete remission after induction are randomized to&#xD;
           either short or long consolidation.&#xD;
&#xD;
             -  Short consolidation: Patients receive mitoxantrone IV on days 1-3 and cytarabine IV&#xD;
                over 2 hours twice daily on days 1-3.&#xD;
&#xD;
             -  Long consolidation: Patients complete short consolidation and then receive&#xD;
                idarubicin IV over 5 minutes once daily on days 1 and 3, cytarabine IV over 2 hours&#xD;
                twice daily and etoposide IV over 1 hour once daily on days 1-3.&#xD;
&#xD;
      Non-intensive chemotherapy*&#xD;
&#xD;
        -  Patients are randomized to 1 of 4 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive oral hydroxyurea as necessary to control WBC count until&#xD;
                treatment failure.&#xD;
&#xD;
             -  Arm II: Patients receive hydroxyurea as in arm I and oral tretinoin daily for up to&#xD;
                16 weeks.&#xD;
&#xD;
             -  Arm III: Patients receive low dose cytarabine subcutaneously twice daily on days&#xD;
                1-10 every 28 days for a minimum of 4 courses.&#xD;
&#xD;
             -  Arm IV: Patients receive cytarabine as in arm III plus oral tretinoin daily for up&#xD;
                to 16 weeks.&#xD;
&#xD;
      NOTE: *Patients with liver function test &gt; 2 times upper limit of normal are not eligible for&#xD;
      nonintensive randomization&#xD;
&#xD;
      Quality of life is assessed at study entry, and then at 1, 3, and 6 months.&#xD;
&#xD;
      Patients are followed at one year.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 2,000 patients (1,200 to intensive arm and 800 to&#xD;
      nonintensive arm) will be accrued for this study over 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1998</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response achievement</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response duration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity by WHO Toxicity Grading after each treatment course</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life EORTC QLQ-C30 at 3 days, 1 month, 3 months, and 6 months from study entry</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource use (use of blood products, antibiotics and days in hospital) after each treatment course</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxyurea</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tretinoin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valspodar</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Acute myeloid leukemia (de novo or secondary) OR&#xD;
&#xD;
          -  Myelodysplastic syndrome&#xD;
&#xD;
               -  More than 10% myeloblasts in the bone marrow&#xD;
&#xD;
               -  Refractory anemia with excess blasts&#xD;
&#xD;
               -  Refractory anemia with excess blasts in transformation&#xD;
&#xD;
               -  Chronic myelomonocytic leukemia&#xD;
&#xD;
          -  No acute promyelocytic leukemia (FAB type M3)&#xD;
&#xD;
          -  No blastic phase chronic myeloid leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  60 and over (younger patients allowed if intensive chemotherapy not indicated)&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No liver function test ≥ 2 times normal (for non-intensive therapy arm)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction within past 6 months in patients receiving daunorubicin or&#xD;
             PSC 833&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent active malignancy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior cytotoxic chemotherapy for leukemia&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan K. Burnett, MD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Wales</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2RR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1E 6AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Seedhouse CH, Grundy M, White P, Li Y, Fisher J, Yakunina D, Moorman AV, Hoy T, Russell N, Burnett A, Pallis M; National Cancer Research Network. Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clin Cancer Res. 2007 Dec 1;13(23):7059-66. doi: 10.1158/1078-0432.CCR-07-1484.</citation>
    <PMID>18056183</PMID>
  </reference>
  <reference>
    <citation>Burnett AK, Milligan D, Hills RK, et al.: Does all-transretinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia? Results from 1666 patients in three MRC trials. [Abstract] Blood 104 (11): A-1794, 2004.</citation>
  </reference>
  <results_reference>
    <citation>Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8.</citation>
    <PMID>19291085</PMID>
  </results_reference>
  <results_reference>
    <citation>Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007 Mar 15;109(6):1114-24. doi: 10.1002/cncr.22496.</citation>
    <PMID>17315155</PMID>
  </results_reference>
  <results_reference>
    <citation>Burnett AK, Milligan DW, Prentice AG, et al.: Modification or dose or treatment duration has no impact on outcome of AML in older patients: preliminary results of the UK NCRI AML14 trial. [Abstract] Blood 106 (11): A-543, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Burnett AK, Milligan D, Prentice AG, et al.: Low dose Ara-C versus hydroxyurea with or without retinoid in older patients not considered fit for intensive chemotherapy: the UK NCRI AML14 trial. [Abstract] Blood 104 (11): A-872, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Pallis M, Truran L, Grundy M, et al.: P-Glycoprotein overexpresion and internal tandem duplications of FLT3 are characteristic of discrete populations of elderly AML patients. [Abstract] Blood 104 (11): A-196, 2004.</citation>
  </results_reference>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

